247 related articles for article (PubMed ID: 33579221)
21. MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.
Lee L; Howitt B; Cheng T; King M; Stawiski K; Fendler W; Chowdhury D; Matulonis U; Konstantinopoulos PA
Gynecol Oncol; 2021 Dec; 163(3):453-458. PubMed ID: 34607711
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the endometrial, cervicovaginal and anorectal microbiota in post-menopausal women with endometrioid and serous endometrial cancers.
Gressel GM; Usyk M; Frimer M; Kuo DYS; Burk RD
PLoS One; 2021; 16(11):e0259188. PubMed ID: 34739493
[TBL] [Abstract][Full Text] [Related]
23. Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
Wang P; Zeng Z; Shen X; Tian X; Ye Q
DNA Cell Biol; 2020 Apr; 39(4):615-630. PubMed ID: 32105510
[TBL] [Abstract][Full Text] [Related]
24. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
Ouyang D; Li R; Li Y; Zhu X
J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
[TBL] [Abstract][Full Text] [Related]
25. HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma.
Banet N; Shahi M; Batista D; Yonescu R; Tanner EJ; Fader AN; Cimino-Mathews A
Am J Surg Pathol; 2021 May; 45(5):708-715. PubMed ID: 33739786
[TBL] [Abstract][Full Text] [Related]
26. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
27. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Factors of Uterine Serous Carcinoma-A Multicenter Study.
Zhong X; Wang J; Kaku T; Wang Z; Li X; Wei L
Int J Gynecol Cancer; 2018 Jul; 28(6):1138-1144. PubMed ID: 29621127
[TBL] [Abstract][Full Text] [Related]
29. The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators.
Zou Z; Zhou S; Liang G; Tang Z; Li K; Tan S; Zhang X; Zhu X
Mol Omics; 2021 Jun; 17(3):438-453. PubMed ID: 34110327
[TBL] [Abstract][Full Text] [Related]
30. Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma.
Kommoss F; Faruqi A; Gilks CB; Lamshang Leen S; Singh N; Wilkinson N; McCluggage WG
Am J Surg Pathol; 2017 Feb; 41(2):161-170. PubMed ID: 27776011
[TBL] [Abstract][Full Text] [Related]
31. Factors prognostic of survival in advanced-stage uterine serous carcinoma.
Holman LL; Pal N; Iglesias DA; Soliman PT; Balakrishnan N; Klopp A; Broaddus RR; Fleming ND; Munsell MF; Lu KH; Westin SN
Gynecol Oncol; 2017 Jul; 146(1):27-33. PubMed ID: 28465008
[TBL] [Abstract][Full Text] [Related]
32. Establishment of the Prognosis Predicting Signature for Endometrial Cancer Patient.
Tang J; Ma W; Luo L
Med Sci Monit; 2019 Nov; 25():8248-8259. PubMed ID: 31678981
[TBL] [Abstract][Full Text] [Related]
33. Fallopian tube abnormalities in uterine serous carcinoma.
Steenbeek MP; Bulten J; Snijders MPLM; Lombaers M; Hendriks J; van den Brand M; Kraayenbrink AA; Massuger LFAG; Sweegers S; de Hullu JA; Pijnenborg JMA; Küsters-Vandevelde HVN; Reijnen C
Gynecol Oncol; 2020 Aug; 158(2):339-346. PubMed ID: 32409160
[TBL] [Abstract][Full Text] [Related]
34. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
[TBL] [Abstract][Full Text] [Related]
35. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
Santin AD; Bellone S; Siegel ER; Palmieri M; Thomas M; Cannon MJ; Kay HH; Roman JJ; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2005 Mar; 192(3):813-8. PubMed ID: 15746676
[TBL] [Abstract][Full Text] [Related]
36. Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y; Zarrella DT; Pooladanda V; Azimi Mohammadabadi M; Kim E; Kumar S; Xu M; Qin X; Ray LJ; Devins KM; Kumar R; Kononenko A; Eisenhauer E; Veillard IE; Yamagami W; Hill SJ; Sarosiek KA; Yeku OO; Spriggs DR; Rueda BR
Br J Cancer; 2024 May; 130(9):1463-1476. PubMed ID: 38438589
[TBL] [Abstract][Full Text] [Related]
37. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
38. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
39. Decreased expression of 14-3-3σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma.
Suzuki F; Nagase S; Suzuki K; Oba E; Hiroki E; Matsuda Y; Akahira J; Nishigori H; Sugiyama T; Otsuki T; Yoshinaga K; Takano T; Niikura H; Ito K; Sasano H; Yaegashi N
Tohoku J Exp Med; 2013 Nov; 231(3):193-9. PubMed ID: 24201220
[TBL] [Abstract][Full Text] [Related]
40. Identification and Function Analysis of a Five-Long Noncoding RNA Prognostic Signature for Endometrial Cancer Patients.
Tang H; Wu Z; Zhang Y; Xia T; Liu D; Cai J; Ye Q
DNA Cell Biol; 2019 Dec; 38(12):1480-1498. PubMed ID: 31539276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
